Tamoxifen blocks estrogen in the breast. Elsewhere in the body it can behave rather like estrogen itself, and the uterus is where that quirk matters. The detail that counts for anyone on the drug: it has been linked with endometrial proliferation, hyperplasia, endometrial cancer and uterine sarcomas, and the American College of Obstetricians and Gynecologists wants women told so.
Under the hood, the benefit and the risk are the same pharmacology working in two places. As ever, the question is who needs watching and how closely.
What gynecologists recommend
ACOG’s Committee Opinion 601 draws a sharp line between two groups of patients. For postmenopausal women on the drug, the advice is close watching for any sign of hyperplasia or endometrial cancer. Premenopausal women carry no known added uterine risk, so they need nothing past ordinary gynecologic care.
What counts as a symptom is spelled out. Any abnormal vaginal bleeding, bloody discharge, staining or spotting should be investigated. That is the trigger, not a calendar.
Screening for its own sake gets short shrift. Unless a patient has been identified as high risk for endometrial cancer, routine surveillance of the uterine lining has not been shown to improve early detection in tamoxifen users, and the committee does not recommend it. If atypical hyperplasia does develop, treatment by a gynecologist should begin and the case for staying on tamoxifen gets another look.
Why women keep taking it
The FDA has cleared it after surgery, for cancer that has spread, and for lowering the odds of a first breast cancer in women at high risk. Cleveland Clinic notes that approval dates to 1998 and that tamoxifen has since become a workhorse of breast cancer care. Most patients take it for five years, sometimes up to 10. Over that time it may lower the chance of recurrence by 30% to 50% before menopause, and by 40% to 50% after it.
The same clinic is candid about the trade. In some patients tamoxifen can add to the odds of a stroke, a uterine cancer or a clotting problem. In a study of 788 women who were taking it for prevention and had no history of breast cancer, the gains beat the dangers for 74% of participants. For 20% they did not.
Most side effects are milder. Menopause-like symptoms lead the list, among them night sweats, hot flashes and dryness, and weight gain or fluid retention can follow. The drug may also cause birth defects, so women need contraception, nonhormonal because hormones can feed this type of cancer, during treatment and for two months after stopping.
That split is the argument for a conversation with a doctor before and during treatment, not after. Women should report abnormal bleeding promptly.
Sources
- Tamoxifen and Uterine Cancer, Committee Opinion 601 (ACOG)
- Tamoxifen: Uses, Side Effects and Risks (Cleveland Clinic)
